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Background: The inclusion of hepatitis B core antibody-positive (HBcAb+) liver donors is a strategy
utilized to increase organ availability. This study examined HBcAb+ transplantation practices to identify
specific factors influencing outcomes.
Methods: Twenty-five HBcAb+ liver transplants were identified retrospectively among 868 adult trans-
plants performed between 1 January 1997 and 31 December 2009. Twelve (48%) recipients had hepatitis
C and five (20%) had hepatitis B. Patient and donor demographics, preoperative morbidity, transplant
data and outcomes were examined. Statistical analysis was completed using Student's t-test or the
Kaplan–Meier method. A P-value of <0.05 was considered significant.
Results: There was no difference in age, body mass index or comorbidities between HBcAb+ liver
recipients and control subjects. Model for End-stage Liver Disease (MELD) scores of >30 were signifi-
cantly more frequent in HBcAb+ liver recipients (32% vs. 15%; P = 0.04). All patients received immuno-
globulin and longterm antiviral therapy as prophylaxis against graft hepatitis B resurgence. No patients
who received HBcAb+ livers developed hepatitis B infection on follow-up. Overall survival at 30 days, 1
year and 5 years in HBcAb+ liver recipients was 92%, 74% and 74%, respectively, compared with 96%,
89% and 76%, respectively, in the control group (P = not significant, log-rank test). All except one of the
deaths in the HBcAb+ liver recipient group occurred within 90 days postoperatively and in patients with
MELD scores >30.
Conclusions: The practice of transplanting HBcAb+ grafts incurs low risk for infection using current
methods of prophylaxis. The highest mortality risk was in the early postoperative period, specifically in
patients with very high MELD scores. This probably reflects the practice of using positive serology grafts
in emergent situations.
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Introduction
In response to an increasing shortage of donor organs, the param-
eters used to select livers for donation have been widened. The
inclusion of donor livers with hepatitis B virus (HBV) core anti-
body (HBcAb), which were previously considered unsuitable, can
reduce the gap between demand and organ availability. These
organs are positive for the core antibody against HBV, but negative
for HBV core antigen (HBcAg) and surface antigen (HBsAg). This
serological pattern indicates prior exposure to HBV infection
without evidence of active infection; however, these donors fre-
quently harbour occult disease which can emerge under condi-
tions of host immunosuppression. The prevalence of HBcAb
among potential donors is as high as 15% in some urban US
centres and a number of strategies to utilize these organs have
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been developed.1,2 These include matching with specific recipients
who are also HBcAb-positive (HBcAb+), as well as the adminis-
tration of prophylaxis against hepatitis B infection to recipients.2–4
Rates of hepatitis B transfection from infected grafts performed
prior to the routine use of prophylaxis therapy were 50–75%.5,6 A
number of approaches were attempted to reduce these rates of
infection, including transplantation into recipients with evidence
of past HBV infection (15% infection rate), and pre-transplant
immunization (10% infection rate).2–4,7 The administration of
immunoglobulin against HBV, as well as antiviral therapy, has
promoted the use of HBcAb+ grafts in non-HBV recipients.8 Since
the introduction of immunoglobulin and antiviral treatment
strategies, the reported incidence of HBV arising from graft
transfection has reduced dramatically.1,9
There have also been conflicting reports on graft and survival
outcomes after the use of HBcAb+ livers.5,10 Earlier reports
suggested significantly worse graft and patient survival rates
in HBcAb+ liver transplants,5 but more recent studies offer
opposing results.10,11
We report the results of a retrospective review of the practices
and outcomes of HBcAb+ donor liver transplants performed at a
single transplant centre. Graft and patient survival in recipients of
HBcAb+ organs were determined and compared with overall sur-
vival rates for all liver transplants performed at this institution
during the study period.We examined the HBV prophylaxis given
to recipients and the incidence of HBV infection post-transplant.
In addition, we investigated specific recipient and donor factors
that may have influenced outcomes.
Materials and methods
Study population
Data were collected retrospectively in this cohort study for all
adult patients who underwent liver transplantation between 1
January 1997 and 31 December 2009.We used the liver transplant
database at our institution to identify recipients of HBcAb+ liver
grafts and confirmed these with data held on the United Network
for Organ Sharing (UNOS) database.
Information collected in the database included: patient demo-
graphics; preoperative medical and surgical histories; operative
details; postoperative condition and recovery status; standard pre-
and postoperative laboratory values; Model for End-stage Liver
Disease (MELD) scores; data on immunosuppression therapy;
data on postoperative complications; data on any retransplanta-
tion, and information on whether the patient survived during the
study period. The causes of recipient death were also reviewed.
The treatments used to prevent recipient HBV infection were
reviewed. Donor characteristics including age, cause of death and
hepatitis B serology were also obtained.
Inclusion criteria
All adult patients who underwent liver transplantation at our
institute from 1 January 1997 to 31 December 2009 were included
in the study.
Exclusion criteria
Adult patients who underwent liver transplantation before 1
January 1997 were excluded because donor hepatitis serologies
were not uniformly maintained prior to that date. Paediatric
patients were excluded because most of them received living
donor organs.
Statistical methods and analysis
Cox regression analysis was performed to determine the respective
influence of these data points on outcome. Fisher’s exact test and
Student’s t-test were used for comparative analysis as applicable.
Analyses of variance (anovas) were performed for multiple group
comparisons. Survival curves were generated using Kaplan–Meier
methods and compared using log-rank tests. A Cox proportional
hazard model was used for survival analysis.
Results
Recipient characteristics
Twenty-five (2.9%) of the 868 recipients of liver transplants per-
formed at this institution between 1 January 1997 and 31 Decem-
ber 2009 received an HBcAb+ liver. The utilization of HBcAb+
donors increased significantly over the period under study.
During 1997–2004, only five of 376 transplants (1.3%) used
HBcAb+ livers, whereas 20 of the 492 liver transplants (4.1%)
performed during 2005–2009 used HBcAb+ organs (P = 0.01).
The HBcAb+ organ recipient group were similar in age (55.1
7.0 years vs. 52.0  10.3 years) and body mass index (BMI) (29.2
 5.2 vs. 27.9  5.4) to the control group. However, the mean
MELD score at the time of operation was higher in the HBcAb+
organ recipient group than in the control group (25 12 vs. 21
9; P = 0.03) (Table 1). There was no restriction policy on the use of
HBcAb+ livers. The most common indication for liver transplan-
tation in both groups was hepatitis C (48% in the HBcAb+ organ
group, 35% in the control group). Hepatitis B virus was more
frequently the reason for transplantation in recipients of HBcAb+
livers (20% vs. 4%). Eleven HBcAb+ liver recipients (44%) had
hepatocellular carcinoma (HCC), compared with 190 (22%)
control group recipients (P = 0.03). The waiting time from listing
to transplantation was longer in the HBcAb+ liver recipient group
(385  749 vs. 230  367 days; P = 0.04). The median wait time
was 89 days in the control group and 139 days in the HBcAb+ liver
recipient group.
Donor characteristics
Donors positive for HBcAb were older (49.6  14.8 years vs.
41.5 17.6 years; P = 0.002) and were more likely to be male and
African American (Table 2). Mean cold ischaemic time was lower
among HBcAb+ donor organs (5.2  2.3 h vs. 6.4  2.5 h;
P = 0.02).
Operative and hospital course after HBcAb+
liver transplantation
Operative time and transfusion requirements were similar in both
the HBcAb+ organ recipient and control groups. There was no
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Table 1 Recipient characteristics
Characteristic Control group
(n = 843)
HBcAb+ organ
recipients(n = 25)
P-value
Age, years, median (range) 53 (18–75) 54 (38–68) 0.14a
Age, years, mean  SD 52.0  10.3 55.1  7.0
BMI, median (range) 27.3 (14.4–47.3) 29 (19.7–38.6) 0.24a
BMI, mean  SD 27.9  5.4 29.2  5.2
Indication for transplantation, n (%)
Hepatitis C virus 295 (35%) 12 (48%)
Hepatitis B virus 33 (4%) 5 (20%)
Alcohol-related 140 (17%) 1 (4%)
Primary biliary cirrhosis 37 (4%) 2 (8%)
Primary sclerosing cholangitis 42 (5%) 0
Non-alcoholic steatohepatitis 30 (4%) 0
Cryptogenic 71 (8%) 3 (12%)
Other 205 (24%) 4 (16%)
MELD score, median (range) 20 (5–50) 22 (8–48) 0.03a
MELD score, mean  SD 21  9 25  12
MELD score 30 737 (86%) 17 (68%) 0.01b
MELD score >30 106 (13%) 8 (32%)
Retransplantation, n (%) 53 (6%) 3 (12%) 0.21b
Wait time, days, median (range) 89 (1–2934) 139 (18–359) 0.04a
Wait time, days, mean  SD 230  367 385  749
aUnpaired t-test, two-tailed P-value.
bFisher's exact test, two-tailed P-value.
HBcAb+, hepatitis B core antibody-positive; SD, standard deviation; BMI, body mass index; MELD score, Model for End-stage Liver Disease score.
Table 2 Donor characteristics
Characteristic Control group
(n = 843)
HBcAb+ organ
recipients (n = 25)
P-value
Age, years, median (range) 43 (7–80) 50 (21–76) 0.002a
Age, years, mean  SD 41.5  17.6 49.6  14.8
Gender, n (%) 0.10b
Male 462 (55%) 18 (72%)
Female 381 (45%) 7 (28%)
Ethnicity, n (%)
White 708 (84%) 11 (44%)
African American 118 (14%) 11 (44%)
Other 17 (2%) 3 (12%)
CIT, h, median (range) 6.2 (0.3–11.9) 4.9 (0.4–11.3) 0.01a
CIT, h, mean  SD 6.4  2.5 5.2  2.3
aUnpaired t-test, two-tailed P-value.
bFisher's exact test, two-tailed P-value.
HBcAb+, hepatitis B core antibody-positive; SD, standard deviation; CIT, cold ischaemic time.
44 HPB
HPB 2012, 14, 42–48 © 2011 International Hepato-Pancreato-Biliary Association
difference in warm ischaemic time between the groups. Postop-
eratively, both groups had similar lengths of intensive care unit
and hospital stay (Table 3).
Patient and graft survival
The mean length of follow-up in HBcAb+ organ recipients was
significantly shorter than in control recipients (2.3 2.0 years vs.
4.3  3.6 years; P = 0.006), which probably reflects our increased
utilization of HBcAb+ grafts in the later years of the study period.
Six deaths (24%) occurred in the HBcAb+ organ recipient group
and 232 deaths (28%) occurred in the control group. All but one
of the HBcAb+ organ recipient deaths occurred in patients with
MELD scores of >30 at transplantation. The cause of death in four
of the six patients was sepsis and five of the six patients died
within 90 days of surgery (Table 4). Sepsis with multi-organ
failure accounted for 66 of the 232 deaths (28%) in the control
group. Most deaths in the control group occurred later. The mean
time to death was 2.8 3.2 years in the control group and 0.17
0.22 years in the HBcAb+ liver recipient group (P = 0.04).
There was no significant difference in patient survival between
the two recipient groups (P = 0.16, log-rank test). Overall survival
rates at 1 month, 1 year and 5 years in HBcAb+ organ recipients
were 92%, 74% and 74%, respectively, compared with 96%, 89%
and 76%, respectively, in the control group (Fig. 1). One patient in
the study group was retransplanted for graft failure caused by
ischaemic cholangiopathy. Graft survival did not differ statistically
between the groups (P = 0.15, log-rank test). Graft survival at 1
month, 1 year and 5 years was 92%, 74% and 65%, respectively, in
Table 3 Hospital course
Control group
(n = 843)
HBcAb+ organ recipients
(n = 25)
P-value
Operative time, h, median (range) 6.6 (3.3–14.4) 6.1 (3.7–10.8) 0.15a
Operative time, h, mean  SD 6.8  1.7 6.3  1.8
PRBC in OR, units, median (range) 3 (0–42) 4 (0–37) 0.52a
PRBC in OR, units, mean  SD 5.2  6.2 6.0  7.2
WIT, min, median (range) 35 (15–80) 33 (18–48) 0.08a
WIT, min, mean  SD 36  8.4 33  6.9
ICU stay, days, median (range) 2 (1–121) 2 (1–12) 0.93a
ICU stay, days, mean  SD 5.9  12 5.7  12
Hospital stay, days, median (range) 7 (6–145) 7 (4–56) 0.67a
Hospital stay, days, mean  SD 11.5  12.9 12.6  12.5
aUnpaired t-test, two-tailed P-value.
HBcAb+, hepatitis B core antibody-positive; SD, standard deviation; PRBC, packed red blood cells; OR, operating room; WIT, warm ischaemic time;
ICU, intensive care unit.
Table 4 Recipient deaths
Control group
(n = 843)
HBcAb+ organ recipients
(n = 25)
P-value
Deaths, n (%) 232 (28%) 6 (24%) 0.82b
Transplant to death, years, median (range) 1.5 (1–12.8) 0.09 (0.01–0.60) 0.04a
Transplant to death, years, mean  SD 2.8  3.2 0.17  0.22
Cause of death, n (%)
Sepsis/multi-organ failure 66 (28%) 4 (67%)
Non-liver cancers 18 (8%)
Recurrent liver cancer 8 (3%)
Graft failure 40 (17%)
Cardiac or stroke 27 (12%) 1 (17%)
Pneumonia 7 (3%)
Intraoperative death 9 (4%)
Unnatural death 6 (3%)
Other 51 (22%) 1 (17%)
aUnpaired t-test, two-tailed P-value.
bFisher's exact test, two-tailed P-value.
HBcAb+, hepatitis B core antibody-positive; SD, standard deviation.
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the HBcAb+ organ group and 94%, 86% and 73%, respectively, in
the control group (Fig. 2).
Transmission of HBV infection and prophylaxis
This institution operated a general policy of HBV vaccination
prior to transplantation; however, seroconversion was not man-
datory for listing or consideration for transplantation using
HBcAb+ livers. All patients, with the exception of two who
died early in the post-transplant period, received postoperative
hepatitis B immunoglobulin (HBIG) prophylaxis irrespective of
their vaccination outcome. The duration of treatment varied over
the period studied. The mean length of treatment was 5.9  7.3
months. All patients received an initial dose of immunoglobulin
intraoperatively. Twenty-two (88%) patients received antiviral
prophylaxis. Initially, the preferred antiviral therapy for HBcAb+
organ recipients was lamivudine. However, more recent recipients
of HBcAb+ livers have been treated with adefovir or entecavir. The
mean length of treatment was 16.6  19.5 months. The current
protocol stipulates that recipients are treated with HBIG intraop-
eratively and are then given intermittent infusions to maintain
HBsAb levels at >150 IU/ml (and >300 IU/ml if the recipient is
positive for HBV). The study patients were monitored for HBV
infection using serology and, more recently, viral DNA by poly-
merase chain reaction. None of the HBV-naïve patients developed
HBV infection from HBcAb+ donors.
Transplantation of HBcAb+ livers into recipients with
high MELD scores
The proportion of patients with MELD scores >30 was signifi-
cantly higher in the HBcAb+ liver recipient group (n = 8, 32%)
than in the control group (n = 106, 13%) (P = 0.01). Five of the six
deaths in recipients of HBcAb+ livers occurred in patients with
MELD scores >30 (Table 4). Survival comparisons using univari-
ate analysis show that overall outcome was significantly worse in
HBcAb+ liver recipients with high MELD scores compared with
the other HBcAb+ liver recipients (P = 0.003) and also with
control recipients with MELD scores >30 (P = 0.002) (Fig. 3).
Discussion
Organ shortages represent one of the greatest challenges facing
transplantation and much effort is focused on increasing the
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Figure 1 Kaplan–Meier curves for overall survival in recipients of
hepatitis B core antibody-positive (HBcAb+ group) and HBcAb-
(control group) organs. Statistical analysis using the log-rank test did
not indicate a significant difference between survival curves (P =
0.16). The table shows survival percentages in the two groups at 1
and 3 months, and 1 and 5 years
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Figure 2 Kaplan–Meier curves for graft survival in recipients of hepa-
titis B core antibody-positive (HBcAb+ group) and HBcAb- (control
group) organs. Statistical analysis using the log-rank test did not
indicate a significant difference between the curves (P = 0.15). The
table shows survival percentages in the two groups at 1 and 3
months, and 1 and 5 years
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number of eligible donors. The past decade has seen increased use
of marginal donors, including older donors, steatotic donors and
donors with positive serologies for viral hepatitis. The identifica-
tion of HBcAb on donor serologies was once considered a con-
traindication to organ use in patients without prior exposure to
HBV or HBV as an indication for transplant.3,6 However, adher-
ence to this policy led to the discarding of otherwise suitable
organs at many centres. Recent data on HBV infection found that
4.7% of the US population are positive for HBcAb; this incidence
increases in older people (50 years) (7.7%) and African Ameri-
cans (12.2%).12 In large urban communities, an estimated 12–15%
of the population will have previous exposure to HBV and posi-
tive serology for HBcAb.1,2,12 In the past 10 years, efforts to trans-
plant HBcAb+ livers have increased. In keeping with the national
trend, we noted a significant increase in HBcAb+ grafts trans-
planted at our institution over the decade (rising from 1.3% to
4.0% of all liver transplants). However, this donor resource
remains underused and mechanisms that safely increase its utili-
zation would expand donor numbers.8,13
The greatest barriers to HBcAb+ graft utilization in HBV-naïve
recipients have been concern that survival outcomes are lower
after HBcAb+ organ transplantation1 and the risk for recipient
infection with HBV.2,3,11,14 Many of the initial studies into patient
outcomes demonstrated survival outcomes that were lower than
expected in HBcAb+ organ recipients.3,5,6 However, when these
earlier studies were performed, HBcAb+ organs were commonly
used in critically ill or HCC patients.1–3,6 Dickson et al.5 compared
recipients of HBcAb+ and HBcAb- organs and found decreased
4-year survival in HBcAb+ organ recipients (55.9% vs. 75.8%).
However, the significant discrepancy in outcome between the
groups was probably confounded by increased disease acuity in
HBcAb+ organ recipients.5 Furthermore, this study was con-
ducted prior to routine prophylaxis treatment with lamivudine or
HBIG and its sample featured a significantly greater rate of de
novo infection (78%) with progression to liver dysfunction. Prieto
et al. (2003) compared patient survival in HBcAb+ organ and
control recipients and, by contrast, failed to demonstrate a signifi-
cant difference in 4-year survival rates (68% vs. 76%).10 More
recently, Yu et al.11 examined UNOS data for all liver transplants
performed between 1994 and 2006 using HBcAb+ donors and
compared these with data for negative controls.11 It is unclear how
many of the HBcAb+ organ recipients received antiviral prophy-
laxis, but the use of HBcAb+ donors was not independently asso-
ciated with worse post-transplant survival.11 In the current study
we found no significant difference in overall or graft survival
between recipients of HBcAb+ andHBcAb- organs, despite, inter-
estingly, higher MELD scores at surgery in the HBcAb+ organ
recipient group.
Numerous strategies are used to prevent HBV transmission,
including passive immunization with HBIG and antiviral
therapies.2,4,9,14–17 Previous studies have demonstrated that, in the
absence of prophylactic therapy, HBV-naïve recipients (HBsAb–
HBcAb–) had an approximately 76% chance of developing HBV
infection and no instances of HBsAb+ HBcAb+ patients develop-
ing HBV after transplantation have been reported.2,5 Conse-
quently, many transplant centres have restricted the use of
HBcAb+ grafts to HBV+ recipients.8,18 The administration of
HBIG has been shown to help prevent HBV transmission, but it
has several limitations including the provision of low protection
in HBV-naïve recipients, low levels of compliance and high costs.14
Lamivudine has been demonstrated to decrease the rate of recipi-
ent infection in HBV-naïve recipients to 2.6%.2 Much debate
remains regarding the use of combined antiviral and HBIG
therapy.2,3,8,14,15,17 Although the addition of HBIG significantly
increases the cost of treatment, its administration appears to be
common practice at most transplant centres.7,17 There are no data
to confirm lower rates of transmission with combined treat-
ment.2,14 More recently, the use of tenofovir and entecavir as pro-
phylactic antivirals of choice has becomemore widespread.16,19We
currently treat all of our patients with HBIG for 3 months and
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Figure 3 Kaplan–Meier overall survival curves for recipients of hepa-
titis B core antibody-positive (HBcAb+ group) and HBcAb- (control
group) organs stratified according to actual Model for End-stage
Liver Disease (MELD) scores at surgery. Statistical analysis using the
log-rank test indicated a significant difference between survival
curves. Recipients of HBcAb+ grafts with high MELD scores had
worse outcomes. aP = 0.003; bP = 0.002
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subsequently provide lifetime antiviral therapy. Similarly to other
recent studies,17,19 we report no recipient HBV infections.
There are several limitations to the current report. This study
examined outcomes at a single transplant centre and therefore the
number of patients included was relatively small. In addition, the
mean duration of follow-up was only 2.3 years in the study
patients and was significantly shorter than in the control group.
Demographic data for the 25 recipients of HBcAb+ livers were
similar to those for the control recipients, although indications for
transplantation and severity of disease at transplantation differed
between the groups. The average MELD score was higher in the
HBcAb+ organ recipient group and an increased percentage of
HBcAb+ organ recipients had MELD scores >30 at the time of
surgery. The average wait time for a liver was significantly lower in
the group with high MELD scores (91 223 days, median = 12.5
days). This suggests a disproportionate utilization of HBcAb+
grafts in critically ill patients with high MELD scores.
Within the scope of this single-centre retrospective study, it is
difficult to demonstrate either statistically or clinically significant
differences between subgroups of HBcAb+ organ recipients. In
our cohort of HBcAb+ organ recipients, we noted an increased
number of deaths and worse survival in recipients with MELD
scores >30. This difference was apparent when this group was
compared with HBcAb+ organ recipients with lowerMELD scores
and also when it was compared with control recipients with
MELD scores >30. Potentially confounding variables relate to the
severity of patient disease and the non-randomized design of
this study.
In summary, we demonstrate in this study that liver transplan-
tation using HBcAb+ grafts can be performed with similar out-
comes to transplants that use HBcAb- grafts. Treatment with
combined antiviral and HBIG prophylaxis leads to very low risk
for recipient infection. Although it remains to be determined
whether specific recipient subgroups should avoid HBcAb+ grafts,
it is clear that this underused resource can be safely utilized to
expand the pool of donor organs.
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